RKRupali Kale

Rupali Kale

*This is an algorithmically generated author record based on publicly available information.

Rupali Kale has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analytical Method Development and Validation for Simultaneous Determination of Simvastatin and Mupirocin Using Reverse-Phase High-pressure Liquid Chromatographic Method

    by Rupali Kale, Pratiksha Shete, Dattatray Doifode, Sohan Chitlange

    This study was aimed to develop and validate the use of reverse-phase high pressure liquid chromatographic method for the estimation of simvastatin (SIM) and mupirocin (MUP) simultaneously. The chromatographic method developed is optimized for flow rate with the column, solvent, and buffer used and mobile phase ratio, molarity, and pH. The validation of the optimized method and the forced degradation studies of both drugs (under acidic, alkaline, oxidation, heat, light, and neutral conditions) were conducted following the The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Kromasil C18 column (250 mm × 4.6 mm, 5 µm) with ultraviolet detection at 224 nm and acetonitrile/phosphate buffer (30 mM, 70:30 v/v, pH 3.5; adjustment done using orthophosphoric acid) as mobile phase at a flow rate of 1.1 mL/min were observed to provide a good resolution for MUP and SIM at retention times of 2.32±0.008 and 13.55±0.254 min, respectively, with high accuracy (percent recovery was 99.69±0.82 for MUP and 101.10±0.02 for SIM) and linearity in the range of 5-30 µg/mL (r2: 0.9969 for MUP and r2: 0.9959 for SIM). The diagnostic limit and the lower limit of determination were 0.771±0.234 and 2.338±0.246 μg/mL for MUP and 0.595±0.282 and 1.803±0.334 µg/mL for SIM, respectively. The validated method was used to understand the degradation behavior of both drugs after the forced degradation studies. The analytical method developed is determined to be specific, sensitive, precise, and accurate for the estimation of MUP and SIM simultaneously in the combined dosage form.


  • Open Access

    Film Forming, Antimicrobial and Growth Promoting Wound Healing Spray Formulation

    by Rupali Kale, Dattatray Doifode, Pratiksha Shete

    Background: Bacterial infections at wound site are one of the major causes for delayed healing. The aim of this study was to develop topical film forming spray having Combination of Simvastatin and Mupirocin which can avoid such infections and provide enhanced wound healing. Methods: Film forming spray formulation having Simvastatin and Mupirocin was formulated using Eudragit E100as film forming agent and Glycerol and Polyethylene glycol (PEG-400) as plasticizers. The effect of these excipients on the formulation was assessed by applying factorial design. Optimized formulation was evaluated for swelling index, spray angle, spray pattern, invitro drug release, evaporation time, average weight per dose, antimicrobial efficacy and in-vivo wound healing was assessed and compared with marketed formulation by excision wound healing model. Results: The optimized batch of topical film forming spray having combination of Simvastatin and Mupirocin was selected based on the results of swelling index and in-vitro drug release at respective drugs. Both the drugs gave more than 80% of drug release within 2 hrs and showed satisfactory physicochemical and mechanical properties along with potent antimicrobial efficacy against S. aureus and E. coli. Developed formulation showed comparative wound healing activity as that of marketed conventional formulation. Conclusion: Topical film forming spray was successfully developed using combination of Simvastatin and Mupirocin Calcium. Antimicrobial activity and results of animal studies indicated safety and efficacy of formulation.